HR 5160
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill aims to extend and update the Stem Cell Therapeutic and Research Act of 2005, which supports research and development into stem cell therapies. Specifically, it increases funding for the C.W. Bill Young Cell Transplantation Program and adjusts the timeframe for cord blood inventory reporting. The reauthorization seeks to maintain and bolster ongoing efforts in this critical area of medical research and treatment. It provides continued support for both basic research and the development of stem cell-based therapies.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
119th CONGRESS — 1st Session
H. R. 5160
IN THE HOUSE OF REPRESENTATIVES
A BILL
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
This Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2025
.
Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended—
by striking appropriated $31,009,000
and inserting the following:
in paragraph (1), as so inserted, by striking the period at the end and inserting ; and
; and
by adding at the end the following:
Section 2(g) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking 2026
and inserting 2031
.